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EVALUATING THE CARDIOVASCULAR RISK OF TESTOSTERONE 
REPLACEMENT THERAPY IN MEN WITH LATE-ONSET HYPOGONADISM 
SHANT ARMEN SIYAHIAN 
ABSTRACT 
 As the major circulating androgen in men, testosterone holds a significant role in 
the maturation and maintenance of male characteristics. Some of its effects include 
inducing significant growth of the penis and testes early in development, producing 
sperm, and contributing to bone mass and muscle strength. Testosterone is synthesized in 
the testes and released into the circulation where it exerts its effects across the body. Its 
negative feedback on the hypothalamus and pituitary glands serve as regulation of the 
hypothalamic-pituitary-testosterone axis.  
 Starting around age 30, testosterone levels have been shown to annually decline 
approximately 1-2% in men. Decline may eventually lead to a deficiency, presenting as 
reduced sex drive, erectile dysfunction, low sperm count, or decreased muscle bulk and 
strength. Many symptoms of testosterone deficiency coincide with old age. Also, the 
threshold of low testosterone at which symptoms manifest can vary from person to 
person. For these reasons, diagnosing testosterone deficiency has proven difficult. 
Nevertheless, certain guidelines have defined late-onset hypogonadism (LOH) as 
testosterone levels below about 200-300 ng/dl with the simultaneous presentation of at 
least one related symptom. Increasing diagnosis of late-onset hypogonadism, colloquially 
known as “Low T”, has led to the enormous growth of the testosterone replacement 
therapy (TRT) market. 
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 Testosterone replacement therapy is the administration of either synthetic or 
endogenous testosterone to restore “above threshold” testosterone levels and improve the 
negative symptoms associated with deficiency. TRT comes in a wide variety of 
formulations and its use has risen steeply over the past decade, with a market currently 
worth around $1.8 billion. Reports estimate that the market for TRT may surpass $5 
billion by 2018.  
However, there is plenty of cause for concern. In its current state, LOH is a 
loosely defined phenomenon whose treatment with TRT has not been confirmed in the 
research-standard large, randomized, placebo-controlled, trial. Furthermore, two recent 
retrospective database studies by Vigen et al. (2013) and Finkle et al. (2014) have 
reported increases in cardiovascular disease risk and mortality with TRT use in men with 
LOH. These studies were preceded with a meta-analysis by Xu et al. (2013) reviewing 
cardiovascular risk of TRT as well as another study measuring TRT effectiveness in 
elderly men by Basaria et al. (2010), which was prematurely halted due to an unsafe 
number of adverse events. The four studies above were analyzed and evaluated as the 
argument against TRT and its potential risk to cardiovascular health.  
On the other hand, there is plenty of evidence associating low endogenous 
testosterone levels with adverse effects and the benefits of TRT in treating LOH. This 
study summarized and evaluated the available evidence of the effects of endogenous 
testosterone levels and testosterone replacement therapy on cardiovascular health, 
including coronary artery disease, congestive heart failure, factors of atherosclerosis, and 
risk factors of cardiovascular disease such as obesity, type 2 diabetes mellitus, 
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dyslipidemia, and inflammatory markers. Additionally, this thesis was written in the 
midst of a recent controversy concerning the field of TRT. Mainstream reporting on the 
results of the aforementioned studies by Vigen et al. (2013) and Finkle et al. (2014) led to 
increasing public concern about the safety of testosterone therapy. The results of these 
studies were met with heavy criticism by the medical field due to their shortcomings in 
design and conduct. The consumer rights advocacy group Public Citizen petitioned the 
FDA to add a black box warning of cardiovascular risk to TRT medications on the 
market. The Androgen Study Group, a group of medical experts and societies committed 
to accurate reporting of information about androgens, countered with a letter of their own 
to the FDA as well as a letter to JAMA requesting that they retract the article by Vigen et 
al (2013). The FDA is currently evaluating these requests as well as the overall risk of 
testosterone replacement therapy on cardiovascular health and mortality. 
The analysis of this thesis proved the argument against testosterone replacement 
therapy unreliable. The four studies contained significant flaws in methodology, 
substandard presentation of data, and were initially built upon a weak foundation of 
evidence. Current evidence shows that low endogenous testosterone levels are associated 
with increased cardiovascular risk, while the results of testosterone replacement therapy 
in treating LOH are predominantly positive. Many of these studies are epidemiological in 
nature, have small sample sizes, and vary in methodology and potential confounding 
factors. Thus, although the advantages reported for testosterone replacement therapy 
seems to trend positive, the need for randomized controlled trial(s) still remains. 
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Diagnosis of LOH and prescription of TRT should be approached with caution and on an 
individualized basis. 
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INTRODUCTION 
Testosterone: Background Science 
Testosterone is the principal circulating androgen of the human male. An 
androgen is either an exogenous or endogenous sex steroid hormone that contributes to 
the development and conservation of masculine characteristics in vertebrates (Meaden & 
Chedrese, 2009). Androgens are primarily synthesized within the Leydig cells of the 
testes, though they can also be produced by the adrenal cortex or be modified to alternate 
forms in peripheral tissues (Nieschlag, 2004). The testes mainly secrete testosterone and 
5α-dihydrotestosterone (5α-DHT), while the adrenal cortex produces 
dihydroepiandrosterone (DHEA), dihydroepiandrosterone-sulfate (DHEAS) and 
androstenedione. Nevertheless, as we shall see, a common steroidogenic pathway links 
the biosynthesis of all androgens together (Nieschlag, 2004).  
The steroidogenic pathway of the human body starts with cholesterol, which our 
bodies can either make from acetate or extract from low-density lipoproteins (LDL) 
circulating in the blood plasma (Nieschlag, 2004). The Leydig cells of the testes collect a 
majority of the cholesterol from LDL and shuttle it to their mitochondria via a lysosomal-
endosomal vesicular system. The first step starts within the inner membrane of the 
mitochondria, which contains low levels of cholesterol and a cholesterol side chain 
cleavage enzyme (P450scc). This step is the rate-determining step of the pathway, either 
speeding up or slowing down steroid synthesis depending on the varying amounts of 
these two elements. Levels of P450scc are controlled by lutenizing hormone (LH) and 
stabilize after puberty. Cholesterol levels, however, stay low and require transfer of 
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cholesterol from the outer mitochondrial membrane to the inner membrane through the 
action of the steroidogenesis activator protein (StAR). Once transferred over, the 27-
carbon cholesterol is converted by P450scc to the biologically inactive 21-carbon 
pregnenolone. Pregnenolone is then relayed to the smooth endoplasmic reticulum, where 
a collection of enzymes dictate its metabolic fate. These enzymes are considered the rate-
limiting step, since the available amounts are often not enough to convert all of the 
pregnenolone to testosterone. Pregnenolone can progress in two different pathways 
depending on the specific enzyme it interacts with. Encountering the 3β-hydroxysteroid 
dehydrogenase/Δ4-Δ5 isomerase (3β-HSD) enzyme, pregnenolone converts to 
progesterone, switching gears from the Δ5-pathway to the Δ4-pathway. The Δ5-pathway 
is the majority pathway in the human testes, where the 3β-HSD enzyme mediates the 
final step to create testosterone. Regardless, both pregnenolone in the Δ5-pathway and 
progesterone in the Δ4-pathway next encounter the 17α-hydroxylase-17,20 lyase enzyme 
complex, which degrades them to 21-carbon intermediates, followed by the 19-carbon 
androgens dehydroepiandrosterone (DHEA) and androstenedione, respectively. The next 
step is mediated by 17-hydroxysteroid dehydrogenase (17β-HSD). In the Δ4-pathway, 
androstenedione is directly converted to testosterone by 17β-HSD. Conversely, in the Δ5-
pathway, DHEA converts to androstenediol via 17β-HSD, after which it undergoes the 
reaction by 3β-HSD to turn into testosterone (Figure 1) (Nieschlag, 2004).  
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Figure 1: Testosterone Synthesis Pathway.  Shown is the biosynthetic pathway of 
testosterone starting from cholesterol extraction from LDL carried in the blood. Note the 
two pathways, the Δ4-pathway and the Δ5-pathway, both of which eventually lead to 
testosterone formation. The pathways are separated by the 3β-hydroxysteroid 
dehydrogenase/Δ4-Δ5 isomerase enzyme (3β-HSD) and may switch over at any step 
along the pathway. Once testosterone is made, it can be metabolized peripherally to either 
DHT or estrogen. Figure taken from Meaden & Chardrese, 2009. 
 
Testosterone can be further metabolized into a more potent androgen or other 
hormones. The 5α-reductase enzymes catalyze the conversion of testosterone into 5α-
dihydrotestosterone (5α-DHT), an androgen that has a higher affinity to androgen 
receptor than testosterone (Nieschlag, 2004). The increased potency is necessary to 
activate certain actions of the androgen in development or maintenance of male 
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characteristics (Nieschlag, 2004). Two isoforms of the enzyme exist in different parts of 
the body, allowing the reaction to take place in the urogenital areas as well as in 
peripheral tissues such as the liver, skin, and certain parts of the brain (Meaden & 
Chardrese, 2009). In another metabolic route of testosterone, cytochrome P450 aromatase 
(P450arom) converts testosterone to the female sex steroid hormone 17β-estradiol within 
both the testes and a wide variety of peripheral tissues (Nieschlag, 2004). At low levels, 
this predominantly female sex hormone also helps in the maintenance of sexual and 
overall male health. About 80% of both 5α-DHT and 17β-estradiol is converted 
peripherally, demonstrating how the ultimate effects of testosterone across the body 
depend on the combination of metabolizing enzymes present within each particular tissue 
(Nieschlag, 2004). Acting as the final frontier for androgens, the liver metabolizes 
androgens to androsterone and etiocholanolone, which eventually are excreted in the 
urine as 17-ketosteroids (Meaden & Chardrese, 2009).   
A common property of steroid hormones is their ability to diffuse through plasma 
membranes (Figure 2) (Nieschlag, 2004). Accordingly, the newly synthesized 
testosterone finds its way out of the Leydig cells through diffusion, following its 
concentration gradient into the interstitial fluid immediately surrounding the cells. From 
there, its concentration gradient and the flow rate of blood vessels nearby dictate its 
release into circulation (Nieschlag, 2004). About 50-60% of circulating testosterone binds 
to sex-hormone-binding globulin (SHBG), 40-50% is bound to albumin, and only 1-2% is 
freely circulating and immediately available for use, known as free testosterone 
(Kaufman & Vermeulen, 2005) (Figure 2).  
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Figure 2:  Basic Path of Testosterone in the Body.  About 6mg of testosterone are 
synthesized per day in the health male, with 95% in the testes and 5% peripherally. Only 
1-2% of androgens are free during transport in the plasma. The remaining 98-99% are 
either bound by albumin or sex hormone binding globulin. Testosterone is converted to 
DHT peripherally, mostly in the prostate gland. Testosterone and DHT are both 
inactivated in the liver prior to excretion. Figure taken from Nieschlag, 2004. 
  
The sum of free testosterone (FT) and albumin-bound testosterone is often called 
“bioavailable” testosterone (BT) (Nieschlag, 2004). The protein bound majority of 
testosterone essentially serves as storage within the body fluids, maintains equilibrium 
with levels in peripheral tissues, and avoids hasty degradation when passing through the 
liver. Regulation of biologically active testosterone occurs at the cellular level. Each 
target cell strikes a balance between the levels of steroid flowing into and out of it. These 
levels are regulated by factors such as blood flow rate, binding protein release rate, 
transport into or out of membranes, etc. Varying rates of either synthesis or degradation 
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due to aging, disease, mutation, drugs, or another cause can lead to an imbalance and 
either testosterone overload or deficiency (Nieschlag, 2004). 
Testosterone and 5α-DHT primarily exert their actions on target tissues by 
binding to the androgen receptor (AR) (Nieschlag, 2004). The AR is a member of a 
steroid receptor superfamily consisting of four common domains, including an NH2-
terminal transactivation domain, a hinge region, a DNA binding domain, and a COOH-
terminal ligand-binding domain. Specifically, the receptor is a ligand-activated nuclear 
transcription factor stabilized by a complex of heat-shock proteins (HSP) that hold it in 
the proper formation to bind its ligand (Nieschlag, 2004). Once its androgenic ligand 
binds to the ligand-binding domain, the AR lets go of the HSPs, dimerizes, and 
translocates from the cytoplasm into the nucleus with the help of a nuclear localization 
signal in the hinge region (Srinivas-Shankar & Wu, 2006). Inside the nucleus, the DNA-
binding domain binds to specific sequences of DNA called androgen response elements 
(AREs) using its two zinc-finger motifs (Nieschlag, 2004). Upon binding to the AREs, 
AR recruits a set of co-activator and co-repressor proteins that interact with the AR and 
its NH2-terminal transactivation domain to initiate transcription, leading to activation and 
repression of specific target genes. All in all, it takes about 30-60 minutes for these 
effects of testosterone to implement. New research suggests testosterone may also be able 
to enact a portion of its effects within seconds to minutes, presumably through a yet 
undiscovered membrane-bound AR. Since the time scale of these actions is too quick to 
involve transcription of the genome, these theorized effects of testosterone are termed 
“non-genomic” (Nieschlag, 2004). 
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As discussed, testosterone and 5α-DHT express their effects by binding to AR and 
transcribing proteins all over the body. Their impact is felt with varying potency 
depending on the AR concentrations, available androgenic levels, and microenvironment 
of the target tissues (Nieschlag, 2004). The first effects of androgens are felt during fetal 
development. For the first few weeks after conception, an assortment of genes creates an 
undifferentiated gonad with both Wolffian (male) and Müllerian (female) precursor ducts 
(Nieschlag, 2004). If the fetus is male, the sex-determining-region of the Y-chromosome 
(SRY) gene stimulates testis formation. The testes begin to secrete testosterone by the 7th 
week of development (Meaden & Chedrese, 2009). Testosterone has the immediate 
impact of initiating LH secretion by the hypothalamus, stimulating Wolffian duct 
development and leading to the deterioration of the Müllerian duct. With the regulatory 
help of SRY and other genes, Sertoli Cells of the testes produce anti-Müllerian Hormone 
(AMH), which binds to cells surrounding the Müllerian ducts to cause it to regress 
(Nieschlag 2004). Some of the testosterone is also metabolized to 5α-DHT, which has its 
own effects on development. Ultimately, the Wolffian ducts stimulated by testosterone 
develop into the epididymis, vas deferens, and seminal vesicle (Nieschlag, 2004). On the 
other hand, 5α-DHT induces formation of the external genitalia (namely the penis and 
scrotum), the urogenital sinus, and the prostate gland while actively inhibiting formation 
of the female external genitalia (Meaden & Chedrese, 2009). The critical period for fetal 
male differentiation lasts from weeks 7-12, during which synthesis of androgens in the 
testes is under the control of human chorionic gonadotropin (hCG) (Meaden & Chedrese, 
2009; Nieschlag, 2004). 
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The anabolic and androgenic effects of testosterone become increasingly evident 
starting at puberty, as modulated by the hypothalamic-pituitary axis (Figure 3) (Meaden 
& Chedrese, 2009). Gonadotropin releasing hormone (GnRH) released by the 
hypothalamus stimulates the pituitary to produce and release lutenizing hormone (LH) 
and follicle-stimulating hormone (FSH) (Nieschlag, 2004). In turn, LH leads to 
testosterone production in the Leydig cells of the testis, while FSH acts on the Sertoli 
cells to aid in spermatogenesis. Testosterone, along with 5α-DHT, estrogen, and inhibin, 
exert negative feedback control on both the hypothalamus and pituitary gland to regulate 
the process. Upon puberty, increasing levels of testosterone exert its effects within and 
outside of the testes, leading to major biological changes in the developing male. One of 
the first changes is significant growth of the testes and penis. Testosterone’s other effects 
on the body which continue during puberty and are maintained during adulthood include 
increased spermatogenesis in conjunction with FSH, deepening of the voice through 
larynx growth, bone mass and skeletal muscle growth which contribute to a growth spurt, 
increased erythropoiesis, thickening of the skin, increased body hair growth as well as 
potential balding, and behavioral changes such as increased aggressiveness and sex drive 
(Nieschlag, 2004; Hall, 2010; Meaden & Chedrese, 2009). 
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Figure 3:  Hypothalamic-Pituitary-Testicular Axis. Notice the negative feedback of 
testosterone, estrogen, and inhibin B on the hypothalamus and pituitary glands. An 
imbalance of this axis, whether through lack of feedback or introduction of another 
factor, may lead to hypogonadism, particularly a form known as hypogonadotropic 
hypogonadism. Testosterone’s peripheral effects include the masculinization that occurs 
during puberty and is maintained throughout adulthood. T=Testosterone; E=Estrogen; 
FSH=Follicle Stimulating Hormone; LH= Lutenizing Hormone. Figure taken from 
Nieschlag, 2004. 
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Hypogonadism 
Population-based cohort studies using data from the Boston Area Community 
Health (BACH) Survey (men 30-79 years old) and the Massachusetts Male Aging Study 
(MMAS) (men 40-69 years old) have estimated the prevalence of symptomatic androgen 
deficiency to be 5.6% and 6%, respectively (Araujo et al., 2004; Araujo et al., 2007a). 
From their MMAS data, Araujo et al (2004) estimated there to be 2.4 million US men 
aged 40-69 with low testosterone levels, with a probable 481,000 new cases each year. 
The gradual age-related decline of testosterone levels in men has been confirmed in many 
studies both cross sectional and longitudinal in nature (Wu et al., 2008; Harman et al., 
2001; Morley et al., 1997; Feldman et al., 2002; Zmuda et al., 1997; Orwoll et al., 2006). 
Results of the Massachusetts Male Aging Study (MMAS) looking at 1,156 men, ranging 
40-70 year in age, for 7-10 years concluded cross-sectional decline of total testosterone 
(TT) at 0.8% per year and 2% per year for bioavailable testosterone (BT) (Feldman et al., 
2002). Longitudinal results were slightly elevated, with TT decline at 1.6%/year and BT 
decline at 2-3%/year. Conversely, SHBG levels increased at a cross sectional rate of 
1.6%/year and a similar longitudinal increase of 1.3%/year. The increase in SHBG levels 
are a possible explanation to the higher percentage decline of bioavailable T levels, 
assuming more SHBG levels means more binding of free T (Feldman et al., 2002). These 
results are generally consistent with results of the Baltimore Longitudinal Study on Aging 
(BLSA) (890 men, ranging from around 20 to 80+ years, followed up to 33 years), the 
New Mexico Aging Process Study (77 men, 61–87 years old, followed for 15 years), and 
the European Male Aging Study (3200 men, 40-79 years old, followed for 4 years) 
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(Harman et al., 2001; Wu et al., 2008; Morley et al., 1997). As seen in Figure 4 from 
Harman et al. (2001) and Kaufman & Vermeulen (1997), increasing proportions of men 
experience subnormal levels of testosterone from the 4th decade of life onwards (Harman 
et al., 2001; Kaufman & Vermeulen, 1997).  
 
Figure 4: Decreasing Testosterone Levels in Aging Men.  In both figures, the 
percentages of healthy men that experience low levels of total testosterone and free 
testosterone increase with each older age group. For both figures, the numbers above the 
bars indicate the number of men included in the study for each particular age group. For 
both figures, the percentages increase starting around the 4th decade. For the figure on the 
right, the black bars represent low levels of total testosterone (<11nmol/l) and the white 
bars represent low levels of free testosterone (0.18 nmol/l). For the figure on the left, the 
black bars represent low levels of total testosterone (11.3 nmol/l) and the striped bars 
represent low levels of free testosterone index (T/SHBG) (0.153 nmol/nmol). Figures 
taken from Harman et al., 2001 (Left) and Kaufman & Vermeulen, 1997 (Right). 
 
 
The pathophysiology of age-related decline in serum testosterone levels can be 
attributed to three different potential mechanisms, either alone or in combination. First, 
primary testicular changes can manifest as reduced Leydig cell secretory reserve and 
diminished overall count, as have been reliably demonstrated in an assortment of studies 
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(Nieschlag, 2004; Kaufman & Vermeulen, 2005). As part of the hypothalamic-pituitary-
testicular axis, reduced testosterone levels translate to a lack of negative feedback on the 
pituitary and hypothalamic glands. Theoretically, pituitary secretion of LH should 
increase, elevating LH levels to access the residual secretory capacity of Leydig cells and 
restore testosterone levels. However, this is not always the case in elderly men. Studies of 
synthetic GnRH administration in vivo have revealed normal pituitary secretory capacity, 
thus eliminating the pituitary gland as the problem and shifting focus to the 
hypothalamus. Elderly men have been shown to have irregularly diminished LH secretory 
pulse amplitude, leading us to believe that the GnRH pulse amplitude might be decreased 
in elderly men. This could be the result of a reduction in the number of GnRH neurons, a 
defect in their synchronization, or a decreased responsiveness to androgens. Interestingly, 
elderly men have been shown to have an increasing sensitivity to androgen feedback, 
eliminating the latter of the potential causes. Still, the true origin of this secondary 
neuroendocrine dysfunction remains unknown. As mentioned earlier, SHBG levels 
increase with age, decreasing the ratio of bioavailable testosterone to total testosterone. 
Young men can make up for the imbalance by increasing their production of total 
testosterone while keeping bioavailable levels constant. Older men, however, must deal 
with the increases in SHBG in conjunction with their primary testicular and secondary 
neuroendocrine dysfunctions, both of which already contribute to low testosterone levels. 
These combined effects culminate in low testosterone levels. The physiological cause of 
SHBG increases remains unknown (Nieschlag, 2004; Kaufman & Vermeulen, 2005). 
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Late-onset hypogonadism (LOH), also referred to as testosterone deficiency 
syndrome, andropause, climacterium, or partial androgen deficiency of the aging male 
(PADAM), is currently defined as a biochemical and clinical syndrome experienced by 
elderly males with certain symptoms in addition to measurable low levels of serum 
testosterone (Endocrine Society Clinical Guidelines, 2010; Wang et al., 2009). The 
current clinical guidelines of the Endocrine Society, the International Society for the 
Study of Aging Male (ISSAM), International Society of Andrology (ISA), European 
Association of Urology (EAU), European Academy of Andrology (EAA) and American 
Society of Andrology (ASA) state that elderly men above total testosterone levels of 
about 300-350 ng/dl (10.4-12 nmol/l), the lower limit of normal for young eugonadal 
men, have a lower likelihood of having any symptoms of androgen deficiency and do not 
require testosterone replacement therapy. Men below 230 ng/dl (8 nmol/l) TT levels 
would benefit from testosterone replacement therapy. Men anywhere between 230-350 
ng/dl (8-12 nmol/l) should get a repeat measurement (Endocrine Society Clinical 
Guidelines, 2010; Wang et al., 2009). Analogously, reference laboratories, where 
measurements are often read, may vary in their established thresholds. For example, the 
Mayo Medical Laboratories list their normal reference range for total testosterone as 240-
950 ng/dl in males aged 19 or older (Mayo Clinical Medical Laboratories, 2014). Rather 
than provide strict definitions, these thresholds give us a general idea of the levels 
considered normal.   
Nevertheless, great variability exists in testosterone thresholds and presentation of 
symptoms across men of all ages (Wu et al., 2010). Kelleher et al (2004) found that men 
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have distinct individual thresholds for testosterone levels, which stay consistent during 
repeat measurements within subjects, but vary widely between men. As a result, one man 
may present with symptoms of androgen deficiency above the “normal” level of 350 
ng/dl, while another stays symptomless at 230 ng/dl (Kelleher et al., 2004). To better 
establish the relationship between testosterone threshold and presentation of LOH 
symptoms, Wu et al (2010) conducted a study correlating testosterone levels with 9 
different symptoms associated with androgen deficiency (three sexual, three physical, and 
three psychological symptoms). They concluded that only the three sexual symptoms 
(erectile dysfunction, frequency of sexual thoughts, frequency of morning erection) were 
significantly associated with low total testosterone levels (<11 nmol/l), thereby 
establishing what they believed the minimum criteria needed to diagnose LOH in elderly 
men (Wu et al., 2010). The clinical guidelines suggest that at least one or more symptoms 
must present along with low testosterone levels in order to diagnose LOH, though authors 
of the Endocrine Society guidelines were unable to agree on what constitutes as “low” 
(Endocrine Society Clinical Guidelines, 2010; Wang et al., 2009). Although LOH 
symptom questionnaires exist, such as the Aging Male Symptom Score (AMS) or the 
Androgen Deficiency in Aging Men (ADAM), they are not recommended for diagnosis 
due to poor specificity (Endocrine Society Clinical Guidelines, 2010; Huhtaniemi, 2014). 
Figure 5 lists additional symptoms that may present with LOH according to the 
Endocrine Society Clinical Guidelines (2010). As evident, symptoms typically associated 
with LOH coincide with the symptomology of the aging male (Kaufman & Vermeulen, 
2005; Vermeulen, 2001). Data considering the clinical impact of androgen deficiency on 
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the symptoms that manifest in the elderly men is often weak and unclear. Thus far, LOH 
can be considered at best one of the many factors that contribute to the symptoms of 
aging (Kaufman & Vermeulen, 2005; Vermeulen, 2001). 
 
 
Figure 5:  Symptoms of LOH. At least one to three of the symptoms on the left should 
be present prior to diagnosis. Many of these symptoms coincide with the symptoms of 
aging. Figure modified from Endocrine Society Clinical Guidelines, 2010. 
 
Though the reasons behind the variability in individual serum testosterone levels 
and thresholds are still unclear, several physiological and lifestyle factors are believed to 
play a role (Nieschlag, 2004). In terms of physiological factors, heredity, body mass 
index (BMI), thyroid hormone levels, insulin, and insulin-like growth factor (IGF-1) have 
all been shown to play a significant role in serum testosterone levels, while ethnicity and 
a polymorphic trinucleotide CAG-repeat on the androgen receptor gene have not 
(Kaufman & Vermeulen, 2005; Nieschlag, 2004). Considering lifestyle factors, diet, 
smoking, alcohol abuse, acute physical and psychological stress, exercise, various acute 
and chronic illnesses, and certain drugs have been shown to directly or indirectly affect 
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testosterone levels (Kaufman & Vermeulen, 2005; Nieschlag 2004). Serum testosterone 
levels also follow a circadian rhythm, with peak levels in the morning and trough levels 
in the late afternoon (Kaufman & Vermeulen, 2005; Endocrine Society Clinical 
Guidelines, 2010). Aging men experience dampened circadian variability, though men 
with low levels may still appear to have normal levels in the morning (Kaufman & 
Vermeulen, 2005). Thus, LOH diagnosis should be based on at least two morning 
measurements (between 7AM and 10AM) for consistency, also considering that the 
current testosterone threshold estimates were established based on morning 
measurements (Huhtaniemi, 2014; Kaufman & Vermeulen, 2005; Endocrine Society 
Clinical Guidelines, 2010). Figure 6 shows a potential flowchart for the diagnosis and 
treatment of LOH.  
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Figure 6:  LOH Diagonsis and Treatment Flowchart. Physicians start from the top of 
the flow chart and follow the path in accordance with their findings. Figure taken from 
Huhtaniemi, 2014. 
 
Testosterone Replacement Therapy 
Testosterone replacement therapy (TRT) is FDA-approved, generally 
recommended and clinically successful in treating classical androgen deficiency 
syndromes of young hypogonadal men such as congenital hypogonadotropic 
hypogonadism or Klinefelter syndrome (FDA, 2014a; Nieschlag 2004; Huhtaniemi, 
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2014; Endocrine Society Clinical Guidelines, 2010). However, treatment of late-onset 
hypogonadism with TRT is a more divisive topic. As discussed earlier, symptoms of 
LOH are often nonspecific, subjective and may not correspond with low testosterone 
levels. Furthermore, inter-individual variations in testosterone levels, altered tissue 
sensitivity to testosterone with age and the fact that testosterone levels are merely an 
indirect biochemical measure of testosterone action make LOH diagnosis more difficult 
than its definition implies. Perhaps most concerning is the lack of a long-term, 
randomized, placebo-controlled trial with adequate power to detect the effects of TRT in 
elderly men (Huhtaniemi, 2014). The FDA does not approve treating LOH with the 
available FDA-approved testosterone replacement therapies (FDA, 2014a). The 
Endocrine Society, also well aware of these difficulties, has refrained on recommending 
TRT to all men with “low” levels, or men that may have LOH, suggesting an 
individualized approach instead based on multiple measurements of testosterone, 
clinically significant symptoms, and thorough discussion about risks and benefits 
(Endocrine Society Clinical Guidelines, 2010). Moreover, patients should be evaluated 
for certain contraindications. Metastatic prostate cancer and breast cancer are absolute 
contraindications of TRT. A serum prostate specific antigen level >4 ng/ml, a hematocrit 
>50%, an unevaluated prostate abnormality, uncontrolled congestive heart failure, and 
severe lower urinary tract symptoms all constitute moderate risk and are considered 
relative contraindications (Endocrine Society Clinical Guidelines, 2010; Huhtaniemi, 
2014). 
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A wide range of testosterone formulations exists with varying modes of 
administration, including oral agents, transdermal patches, gels and buccal tablets, 
parenteral intramuscular injections and subcutaneous pellet implants (Figure 7) (Srinivas-
Shankar, 2006). Unmodified testosterone that passes through the liver has a short half-
life, so testosterone is often modified to stay effective for longer periods of time.  
Alkylation of the 17-hydroxy position creates oral testosterone that avoids immediate 
degradation in the liver due to a longer side chain, though most of these formulations 
aren’t typically used. In contrast, esterifying testosterone at the 17β-hydroxy position 
makes a less polar molecule, allowing for solubility in oils and a more gradual systemic 
release, but requiring intramuscular injection due to a shorter side chain (with the 
exception of testosterone undecanoate) (Shrinivas-Shankar, 2006). Preparations also 
contrast in attributes like cost, ease of use, frequency of use, nature of fluctuations in 
testosterone levels, and side effects (Brawer, 2004). Ultimately, patients determine which 
type best suits their needs through physician consultation.  
	  20	  
Table 1:  Testosterone Formulations.  List of all available testosterone formulations. 
Patients, with physician guidance, decide which one to use based on how their needs 
match with the drug’s attributes. Figure modified from Endocrine Society Clinical 
Guidelines, 2010. 
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 Certain potential benefits and risks for TRT in men with LOH have been 
identified. TRT has been shown to improve libido, erectile functioning and sexual 
satisfaction in men with LOH, but treatment effects have been small and data is limited 
(Nieschlag, 2004; Huhtaniemi, 2014; Bassil, 2009). Data on bone mineral density have 
shown improvements, but its effect on fractures, a major concern with aging, is to be 
established. Significant decreases in fat mass and increases in lean body mass have been 
demonstrated without a change in body weight. Studies have also shown improvements 
in cognition, well-being, and mood. Increases in muscle mass and strength have been 
observed, but are inconsistent. In terms of risk, most commonly found is erythrocytosis 
(hematocrit >50%). Potential increased risk of prostate cancer and benign prostatic 
hyperplasia has been considered, but evidence is non-conclusive. Some oral forms of 
TRT have been associated with liver toxicity and tumors. Other effects of TRT may 
include exacerbating sleep apnea, increased sodium and water retention, incidence of 
certain skin reactions and possible gynecomastia, particularly in obese elderly men. 
Overall, there are limitations in what we know about both the benefits and risks of TRT 
owing to evidence lacking in adequate power, duration, proper control and confounded 
by the diseases and symptoms of old age (Nieschlag 2004; Huhtaniemi, 2014; Bassil, 
2009). The relationship between cardiovascular health and TRT is plagued with much of 
the same uncertainty. Before we delve into the main subject matter of this thesis, namely 
evidence concerning the association of TRT and cardiovascular health, an overview of 
how these topics intertwine might prove helpful. 
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Cardiovascular Disease and Testosterone 
Men experience a gradual decline in their testosterone levels starting around age 
40 (Kaufman & Vermeulen, 1997). Men aged over 45 years old also have an increasing 
risk for heart attack related to coronary artery disease (CAD), or atherosclerosis of the 
coronary arteries (AHA, 2014). The coincidence of these facts led researchers to explore 
how testosterone interacts with CAD. In fact, testosterone replacement therapy was 
employed in the treatment of angina pectoris as early as 1942 (Lesser et al, 1946), just a 
few years after it was first isolated as a chemical in 1935 (Nieschlag & Nieschlag, 2014). 
Atherosclerosis, or the gradual buildup of plaque in the endothelial walls and 
narrowing of blood vessels, is the cause of many cardiovascular conditions, often leading 
to heart attack, stroke, or death (NIH, 2011a). Risk factors of atherosclerosis include 
elevated cholesterol levels, inflammatory markers, intima-media thickness, obesity, and 
type 2 diabetes mellitus (NIH, 2011b; AHA, 2014). Since testosterone levels may have an 
influence on CAD and atherosclerosis, researchers have considered that they may also 
have an effect on its risk factors and have started to investigate these associations as well. 
Finally, researchers have started looking at the relation of testosterone levels and another 
cardiovascular disease known as congestive heart failure (CHF), a chronic condition that 
results when the heart cannot generate enough force to pump oxygenated blood 
throughout the body (AHA, 2012). 
Recent Controversy 
 In November of 2013, Vigen et al. (2013) published a study in the Journal of the 
American Medical Association (JAMA) associating TRT with increased cardiovascular 
	  23	  
disease risk and mortality. A couple of months later, in January of 2014, Finkle et al. 
(2014) published another study that came up with a similar conclusion: that TRT 
increases risk of non-fatal MI. Both articles were met with heavy criticism from medical 
experts and researchers (Goldstein, 2014; Traish et al, 2014; Ho et al, 2014). Both articles 
also attracted the interest of major media outlets, including the NY Times, USA Today, 
and NBC News, whose reports on the topic increased public awareness as well as 
concern and attracted the attention of consumer rights advocacy group Public Citizen 
(NY Times, 2014; USA Today, 2013; NBC News, 2013). Public Citizen followed with a 
petition to the Food and Drug Administration (FDA) requesting them to add a black-box 
warning label to all testosterone treatments indicating cardiovascular risk (Public Citizen, 
2014). The Androgen Study Group (ASG), a group of professional researchers and 
physicians committed to accuracy regarding testosterone treatment, responded to the 
petition with their own letter to the FDA urging them to deny the request and presenting 
them with research evidence in support of their stance (Androgen Study Group, 2014a). 
The ASG also wrote a letter to JAMA requesting retraction of the article by Vigen et al. 
(2014) (Andogen Study Group, 2014b). The FDA is currently evaluating the risk of 
stroke, heart attack, and mortality associated with testosterone therapy (FDA, 2014a). 
Specific Aims/Objectives 
 In the midst of an FDA evaluation on the cardiovascular risk of testosterone 
therapy is an imperative need to understand the available research evidence upon which a 
decision would be based. There is an immense amount of significant literature regarding 
the cardiovascular benefits of testosterone therapy, yet not without its limitations. 
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Conversely, the recently published articles associating an increased cardiovascular risk 
with testosterone therapy are alarming, but require more rigorous scrutiny.  
Thus, this thesis aims to: 
1. Summarize and analyze the conclusions and limitations of published 
studies looking at the association between testosterone replacement 
therapy and cardiovascular health. 
2. Summarize and analyze the procedures, results, and conclusions of the 
only four research articles associating testosterone replacement therapy 
with increasing cardiovascular risk. 
3. Conclude with a new understanding of testosterone replacement therapy in 
its current context as well as an appropriate approach for men with late-
onset hypogonadism. 
 
A principal accomplishment of the specific aims above would be to embody the 
overarching theme of medicine through an evaluation and suggestion of the proper course 
of action against a known framework of benefits and risks. As an objective to live up to 
while perusing the contents of this thesis, keep in mind this theme. 
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PUBLISHED STUDIES 
 
Against Testosterone Therapy  
In their petition to the Food and Drug Administration, Public Citizen mentioned 
only four articles with significant evidence associating testosterone therapy with 
increased cardiovascular risk (Public Citizen, 2014). The following is a review of the 
methods, results, and conclusions of these four articles for the purposes of evaluating the 
validity of their claims. 
1. Adverse Events Associated with Testosterone Administration. Basaria et al., NEJM, 
2010.  
The Testosterone in Older Men with Mobility Limitations (TOM) trial was 
interested in the possibility of treating low testosterone levels and limited mobility in an 
elderly male population with testosterone therapy. Basaria et al. (2010) designed a 
randomized, placebo-controlled, double-blind trial to determine the efficacy of a 
testosterone gel (Testim) in improving the strength and mobility of the participants as 
measured by certain exercises. The study started in September 2005 and was terminated 
in December of 2009 per request of the data and safety monitoring board due the risk 
posed from a larger number of adverse events recorded in the testosterone group.  
All participants involved were men over 64 years old living at one of three 
community centers, with limited mobility as defined within the study and morning-
measured total serum testosterone levels ranging 100-350 ng/dL (3.5-12.1 nmol/L) or 
free serum testosterone levels less than 50 pg/mL. A total of 209 men, averaging 74 years 
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old, participated and were randomized into a testosterone group (106 men) and placebo 
group (103 men), with a large proportion of both groups having cardiovascular disease, 
diabetes, hyperlipidemia, obesity, and hypertension at baseline. The testosterone 
prescription started at 100mg of gel and was adjusted after two weeks to a dosage aimed 
at maintaining the testosterone levels between 500 and 1000 ng/dL. The study was 
designed to measure the maximal leg strength as a primary endpoint using a leg press 
exercise and several secondary endpoints including tests for chest strength, walking, stair 
climbing, and functional movement. The trial period for each participant was 6 months 
with a 3-month observation phase following treatment.  Physical measurements were 
collected at baseline and at the end of the 6 months for those subjects who completed the 
full treatment.  For those subjects stopping earlier than 6 months, these physical 
measurements were taken at the point of discontinuation.  
Of the 209 men who participated, a total of 176 men had a baseline and at least 
one other post-trial measurement, and were included in the final analyses. Of these 176 
men, 129 had undergone the complete 6 months of treatment while 47 had completed 12 
weeks or more. The testosterone group averaged at 574±403 ng/dL (19.9±14.0 nmol/L) 
of testosterone while the placebo group average was 292±160 ng/dL (10.1±5.6 nmol/L). 
The testosterone group also had significantly greater increases in the primary and 
secondary endpoints of strength measurements. The data and safety monitoring board 
discontinued the study before it enrolled the target number of 252 men due to a 
significant disparity in adverse events between the two groups. The testosterone group 
resulted in 23 participants with cardiovascular related events compared to 5 participants 
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in the placebo group. The adverse events were categorized into three different groups. 
The first group of events was according to the Medical Dictionary for Regulatory 
Activities (MedDRA) System Organ Class classification of cardiac events. The second 
group included the MedDRA cardiac events as well as events deemed “cardiovascular in 
nature” by the safety board. The final group included events in direct relation to 
atherosclerosis. Most concerning to the safety board was that the testosterone group had 
10 events compared to 1 event in the placebo group according to the MedDRA grouping 
of cardiac events. Adjusting for characteristics such as age, body mass index (BMI), 
smoking status and cholesterol levels did not alter the significant difference in results 
between the groups, which carried on through the observation phase of the trials. 
Nevertheless, the outcome of this study is not without its limitations, which will be 
examined in the Discussion section.  
2. Testosterone therapy and cardiovascular events among men: a systematic review and 
meta-analysis of placebo-controlled randomized trials. Xu et al., BMC Medicine, 2013. 
The scientific literature is lacking a randomized controlled trial aimed at 
examining the relationship between testosterone therapy and cardiovascular risk. In the 
spirit of contributing to this gap of knowledge, Xu et al. conducted a meta-analysis 
focusing on the cardiovascular related adverse events in randomized controlled trials of 
testosterone. A team of four took on the task, with the first two conducting a 
comprehensive literature search and selection and the remaining two running the 
statistical analysis. The search for English articles of testosterone trials was conducted 
using Pubmed and the World Health Organization (WHO) Clinical Trials Registry 
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Platform. A total of 1,882 articles came up in the Pubmed search, 1 in the WHO search, 
and 2 from previous meta-analyses. This comprehensive search was further narrowed to a 
total of 34 after the following criteria were applied: inclusion of randomized placebo-
controlled testosterone trials at least 12 weeks in length with cardiovascular related 
events reported in both the placebo and testosterone arms. Xu et al. defined 
cardiovascular events as any events the authors referred to as cardiovascular in nature, or 
otherwise described by the International Statistical Classification of Disease (ICD) 
version 10 Chapter IX . The authors also analyzed the events by “seriousness”, with 
seriousness denoting the severity of the cardiovascular event either as described by the 
author, its impact on one’s life, or according to a list of events deemed serious by the 
researchers. Due to an inability to completely account for accurate interpretation and 
cohesiveness of adverse events reported, the effects of testosterone on cardiovascular risk 
were analyzed in relation to funding source as well cardiovascular associated death.  
The 34 articles were brought down to a final total of 27 after 7 more articles were 
cut for not clarifying cardiovascular events by study arm. These 27 studies accounted for 
a total of 180 cardiovascular events among 2,994 men, with 1,733 of the testosterone arm 
and 1,261 of the placebo arm. Sensitivity analyses showed that the 13 studies receiving 
funding from pharmaceutical companies varied from the non-funded studies in several 
ways: a lower incidence of cardiovascular related events (4%) compared to the non-
funded (8%) and testosterone therapy did not have an effect on the incidence of events as 
opposed to an increased risk in the non-funded studies. A total of 22 cardiovascular 
related deaths were observed in the testosterone arm compared to only 11 in the placebo 
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arm. In assessing the quality of events that were counted as cardiovascular related, 10 
studies specified their events per study arm within a table, while 17 studies required a 
deeper look into the literature and some conjecture to account for events withdrawn from 
the main analysis. Two trials were concluded sooner than planned as a result of the 
adverse events. This meta-analysis is one of several other meta-analyses aimed at 
determining the risk associated with testosterone treatment. In the discussion, we will 
delve more into the implications of its results as it stands on its own as well as within the 
context of these comparable meta-analyses. 
3. Association of Testosterone Therapy with Mortality, Myocardial Infarction, and 
Stroke in Men with Low Testosterone Levels. Vigen et al., JAMA, 2013. 
Vigen et al. decided to revisit the results of the TOM trial with a retrospective 
analysis of elderly veterans by assessing whether the presence of cardiovascular disease 
would affect the impact of testosterone therapy on resultant adverse outcomes of patients. 
By referring to a database of clinical information about veterans from the Veteran Affairs 
(VA) system and applying rigorous statistical methods, they concluded that testosterone 
therapy does, in fact, increase the likelihood of adverse events. From the date when it was 
first published, November 6, 2013, the study has undergone two separate corrections 
lending doubt to their validity. Currently, the Journal of the American Medical 
Association (JAMA), the journal in it was published, is under intense scrutiny to retract 
the article by the Androgen Study Group, 29 additional medical societies, and over 150 
experts from around the world. 
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The dataset employed in this study, coming from 76 VA laboratories across the 
US, included the clinical information and characteristics of men as they were entered into 
the VA Clinical Assessment Reporting and Tracking (CART) system from 2005-2011. 
Inclusion criteria were male veterans having undergone coronary angiography with a 
testosterone level measured to be lower than 300 ng/dL. Symptoms of LOH were not 
required for inclusion in the study. Exclusion criteria included all men that had started 
testosterone therapy before their baseline testosterone levels were entered into the system, 
before having their coronary angiography reading, and after a recent myocardial 
infarction (MI), as well as men with incomplete cardiovascular data or with data 
contraindicative of testosterone therapy. Applying these criteria, the researchers ended up 
with 8,709 men, of which 20%, 50%, and 80% had prior MI history, diabetes, and 
coronary artery disease (CAD), respectively. 
Using data from the pharmacy, these men were further divided into a testosterone 
therapy group, or men who received a post-coronary angiography prescription for 
testosterone therapy (could be either patch (most commonly 2.5mg/24 hours), gel (most 
commonly 1% 5g packet), or injection (most commonly 200mg/mL)) and a non-
testosterone therapy group, or men without a prescription. The testosterone therapy group 
was assumed to have been compliant with their prescription as long as they either had 
their information recorded in the database or reached one of the primary endpoints. The 
primary endpoint constituted the number of days until one of three separate events 
occurred: death, myocardial infarction, or stroke. In addition, patients were determined to 
have coronary artery disease if the results of their coronary angiography procedure 
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indicated greater than or equal to 20% blockage of their coronary arteries, a definition 
“based on standardized definitions of flow limiting stenosis” (Vigen et al., 2013).  
The inherent nature of a retrospective database analysis prevents randomization. 
Thus, a variety of rigorous statistical methods were applied to make up for the study’s 
inability to randomize who was prescribed testosterone therapy. Researchers applied a 
weighting system with 53 different variables meant to balance against any confounding 
factors that may have inclined a patient to receive testosterone therapy. These variables 
fall under three categories; demographic characteristics, comorbidities, and clinical 
procedures. The weighting system was used for every patient that reached the primary 
endpoint. Sensitivity analyses evaluated whether the effects of the testosterone group vs. 
the non-testosterone group on the primary endpoint would interact with cardiovascular 
risk factors or medications. 
The purpose of the study was to see whether testosterone therapy led to an 
increased risk in adverse events in elderly men and if cardiovascular disease would have 
an influence on this effect. The testosterone therapy group consisted of 1,223 men, of 
which 123 reached the primary endpoint. Comparatively, 1,587 of the 7,486 non-
testosterone therapy group reached primary endpoint. After application of statistical 
modifications, including the weighting system, this translated the rate of an adverse event 
occurring within 3 years to a 19.9% decrease in survival for the non-testosterone therapy 
group compared to a 25.7% decrease in survival for the testosterone therapy group, a 
non-significant 5.8% difference. Thus, testosterone therapy was associated with an 
increased risk in adverse events. This finding was consistent both during the presence and 
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absence of coronary artery disease, and there was no significant change in effect found 
due to the presence of CAD. The risk of testosterone therapy did not significantly change 
among usage of the patch (774 men, or 63%), gel (13 men, or 1.1%), or injection (436 
men, or 35.7%). Other statistics related to the testosterone therapy group included: 215 
men (17.6%) filled 1 prescription vs 1008 men (82.4%) who filled more than one; of the 
60% who had their testosterone levels checked during the treatment period, the average 
change in levels was from 175.5 ng/dL to 332.2 ng/dL; for those who refilled more than 
once, the average length of their treatment when considering the length from their first to 
last filled prescription was 376 days.  Finally, the sensitivity analyses conducted showed 
no notable changes in the outcome of results. These results were highly disputed, 
questioned, and criticized by the medical community, the reasons for which will be 
discussed later. 
4. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy 
Prescription in Men. Finkle et al., PLOS ONE, 2014. 
The most recent study showing evidence of increased cardiovascular risk with 
testosterone therapy, conducted by Finkle et al., is the second restrospective database 
analysis of the four studies. The previous 3 studies all had relatively smaller sample sizes 
of mostly older men, limiting them from adequately assessing the risk of specific adverse 
events and of the presence of cardiovascular disease in relation to testosterone therapy. 
With the use of a significantly larger database, Finkle et al. were able to focus on whether 
testosterone therapy would increase risk of non-fatal acute myocardial infarction in a 
broader age group and for those already with cardiovascular disease.  
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The Truven Health MarketScan Commercial Claims and Encounters Database 
provided information about the patient’s record of enrollment, age, sex, diagnoses, 
treatments, and prescriptions between 2006 and 2010. Patients were selected if they had 
at least 22-25 months of continuous data with either a 90-day or 91-180 day post-
prescription follow up. The data was further stratified into men that took estrogen-free 
testosterone therapy (total of 55,593 men) and men with a phosphodiesterase type 5 
inhibitor (PDE5I, also known as drugs like Viagra or Cialis) prescription first filled 
between 2008-2010 (total of 167,279 men) as a comparison group. Certain information, 
including details on prescription compliance, prescription indications, race, clinical lab 
results, and relevant factors, was not included. Men subscribed to a multitude of forms of 
testosterone therapy, most frequently testosterone gel, synthetic testosterone cypionate, 
micronized testosterone, and transdermal testosterone. Finkle et al. chose PDE5I as the 
comparison drug because it had similar prescription indications as TT, did not pose a risk 
to the cardiovascular system, was typically given to older men, and was not functionally 
or metabolically related to testosterone. The pre-prescription period was defined as 12 
months prior to prescription initiation, and the post-prescription follow-up was 90 days 
after first prescription, unless they refilled their prescription earlier or had the primary 
endpoint diagnosis of acute MI. If prescription was not refilled, patients were followed 
the extra 91-180 days, assumed to be a period with low drug use. If patients had their 
initial TT or PDE5I prescription during follow-up or had a history of MI before initial 
prescription, they were not included in the post-prescription analysis. Patient information 
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regarding diagnoses linked to MI (according to ICD 9 code) and prescriptions prior to the 
study initiation were also collected as covariates to examine its effect on the results.  
Finkle et al.’s primary analysis evaluated whether TT affected risk of acute 
myocardial infarction, compared against the patient’s previous diagnosis history of 
cardiovascular disease and the relative rate of occurrence in PDE5I prescription. To 
measure the effect of TT, they estimated the ratio of post-prescription MI incidence rate 
to pre-prescription MI incidence rate (RR). The relative rates of effect between PDE5I 
and TT were estimated by weighing the PDE5I patients to balance pre-prescription MI 
incidence rates of both groups. Another statistical measure employed was the ratio of rate 
ratios (RRR), composed of the post-prescription rate ratio of TT to PDE5I as numerator 
and the pre-prescription rate ratio of TT to PDE5I as denominator. 
The RR of all TT patients came out to be 1.36, meaning more MI’s occurred in 
the TT post prescription interval than the pre-prescription interval, with men 65 and older 
having a RR of 2.19 and men under 65 having a smaller RR at 1.17. This reflected a 
study-wide trend of increasing RR with older age. For those with the 91-180 day non-
refill post-prescription interval, RR was 0.98 for 65 and older while 1.15 for under 65. 
After weighting to balance pre-prescription MI rates between PDE5I and TT groups, 
which were 3.48 per 1,000 person years, the total PDE5I RR came out to be 1.08, with 
1.15 for 65 and older and 1.06 for under 65. The RRR of comparing TT to PDE5I was 
1.27. Finally, men under 65 in the TT group with a history of cardiovascular disease 
diagnosis had a RR of 2.90, decreasing to 2.17 as they aged (65 and older group). In 
comparison, men under 65 in the TT group without a history of cardiovascular (CV) 
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diagnosis had a RR of 0.90, increasing to 2.21 for the 65 and older.  PDE5I values of RR 
for men with and without CV disease diagnosis were all less, with a decreasing RR trend 
as they aged. An evaluation of the study methods and the implications of these results in 
the discussion section will cover the final portion of the anti-testosterone therapy side of 
the argument. 
 Endogenous Testosterone, Testosterone Replacement Therapy and 
Cardiovascular Health 
 The literature on cardiovascular health and testosterone is vast, touching upon 
many aspects but firmly concluding upon none. In stark contrast to the detailed dissection 
of the articles against testosterone, this section will briefly summarize our understanding 
of the relationship between endogenous testosterone levels, testosterone replacement 
therapy (TRT), and cardiovascular disease and its risk factors.  
Associations Between Endogenous Testosterone Levels and Cardiovascular Risk 
Factors 
 The American Heart Association (AHA) and World Heart Federation (WHF) both 
list Type 2 Diabetes Mellitus (T2DM), obesity, and dyslipidemia among the risk factors 
for cardiovascular disease that can be modified or controlled (AHA; WHF). In addition, 
inflammatory markers such as high-sensitivity C-reactive protein (hsCRP) are considered 
risk factors for atherosclerosis and have been linked to interacting with the 
aforementioned risk factors to increase cardiovascular risk (Libby, 2002). We will 
discuss these factors in terms of the literature evidence of their relation to endogenous 
testosterone levels in men. 
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Type 2 Diabetes Mellitus 
 The link between men with T2DM and low endogenous levels of testosterone is a 
well-acknowledged finding. In 1978, Shahwan et al. were one of the first to hint at a 
possible connection, concluding that men taking anti-diabetic oral agents had 
significantly lower testosterone levels than men with either insulin treatment or a 
controlled diet (Shahwan et al., 1978). Andò et al. (1984) and Barrett-Connor et al. 
(1990) came up with more direct evidence when they found lower levels of total 
testosterone and free testosterone (FT) in diabetic men compared to controls (Ando et al., 
1984; Barrett-Connor et al., 1990). Since these initial discoveries, a considerable amount 
of literature has been published in support of these results. Ding et al. (2006) and Corona 
et al. (2011) conveniently summarize much of the evidence through their recent meta-
analyses. Ding et al. (2006) concluded that among 3825 men across 36 cross-sectional 
studies, men with T2DM had significantly lower total testosterone levels compared to 
controls and men with higher TT (15.6-21.0 nmol/L) had a 42% lower risk of T2DM than 
men with low TT (7.4-15.5 nmol/L). Ding et al. (2006) was unable to evaluate the 
relation with FT levels due to a lack of reliable evidence. Corona et al.’s (2011) meta-
analysis consisted of 27 cross-sectional studies of 1822 diabetic men and 5 longitudinal 
studies enrolling 2700 men, for which they analyzed data on total testosterone, free 
testosterone, and SHBG. Their results agreed with Ding et al.’s findings, with lower TT, 
FT, and SHBG in diabetic men compared to controls. Since they were able to confirm the 
decrease in FT levels, Corona et al. also concluded that the decrease in TT is not solely 
due to a drop in the SHBG levels (Corona et al., 2011). 
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 Researchers have approached the association between testosterone levels and 
T2DM through a variety of methods. Several studies have found an increased risk of 
developing Type 2 diabetes at lower levels of TT, FT, and SHBG. Colangelo et al. (2009) 
concluded that within the study group of 3,156 men, the lowest risk of developing T2DM 
was in the highest quartiles of TT (mean: 22.05 nmol/L) and SHBG (mean: 70.1 nmol/L) 
levels. However, this association was not apparent in the bioavailable testosterone 
quartiles (Colangelo et al., 2009). Two large prospective population-based cohort studies 
had similar results. Laaksonen et al. (2004) found that after 11 years of follow-up of 702 
men, participants in the lowest quartiles of SHBG (<28.3nmol/L), FT (<253pmol/L) and 
TT (<15.6 nmol/L) levels were 1.7 to 4.3 times more likely to develop T2DM, though FT 
levels did not reach significance. Vikan et al. (2010) demonstrated that in 1454 men with 
an 11-year follow-up, higher TT (>16.2 nmol/L) and SHBG (>63.0 nmol/L) levels 
decreased the risk of developing T2DM, but their association lost significance when 
adjusting for waist circumference. Finally, Keating et al. (2010) took a novel approach 
with an observational study investigating whether androgen deprivation therapy (ADT) 
given to 14,597 men with prostate cancer in the Veteran’s Healthcare Administration 
would have an effect on the incident rates of T2DM and cardiovascular disease. The 
results corroborated the findings of previous studies, showing that ADT using a 
gonadotropin releasing hormone agonist significantly increased incidence of T2DM, 
coronary heart disease, stroke, myocardial infarction, and sudden cardiac death (Keating 
et al., 2010).  
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Obesity 
 The Body Mass Index (BMI) is commonly used as an indicator of obesity (CDC, 
2011). A meta-analysis of 31 studies conducted by MacDonald et al. (2010) looked at the 
relationship between BMI and levels of testosterone. The conclusion derived a strong 
negative association between TT and SHBG with BMI, and a weak negative association 
between FT and BMI (MacDonald et al., 2009). Mulligan et al. (2006) conducted a study 
comparing the BMI of 1326 eugonadal patients with 836 hypogonadal patients, in which 
they concluded that the BMI averaged at 31.5 for hypogonadal patients opposing a mean 
of 28.5 for eugonadal patients (Mulligan et al., 2006). In the osteoporotic fractures in men 
(MrOS) study of 2416 men run by Ohlsson et al. (2011), they found that the highest 
(28.1) mean BMI levels were in the lowest quartile of TT levels, compared to the highest 
quartile of TT levels, in which mean BMI was 24.9 (Ohlsson et al., 2011). 
Dyslipidemia 
 When lipid levels, including Total Cholesterol (TC), High Density Lipoprotein 
(HDL), Low Density Lipoprotein (LDL), and triglycerides, stray from normal levels, they 
become critical risk factors for cardiovascular disease (Fodor, 2011). Studies by Haffner 
et al. (1993), Van Pottelbergh et al. (2003), Wranicz et al. (2005), Agledahl et al. (2008), 
and Vaidya et al. (2008) are inconsistent, all varying in significance when associating 
testosterone levels with TC, LDL, HDL, and triglycerides.  
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Inflammatory Markers (High-Sensitivity C-Reactive Protein) 
 Measurements of high-sensitivity C-reactive protein (hsCRP), the first described 
acute phase protein of inflammatory response, have been shown to predict cardiovascular 
disease risk (Ridker, 2001; Pepys & Hirschfield, 2003). The possibility of testosterone 
influencing cardiovascular health through its interaction with inflammation has led 
researchers to look at the association between levels of inflammatory markers, 
particularly hsCRP, and endogenous testosterone. Once again, the data thus far is 
conflicting. Certain studies have correlated low testosterone levels with high levels of 
hsCRP, indicating a potential role of the sex hormone in inflammation (Bhatia et al., 
2006; Zhang et al., 2013; Kapoor et al., 2007; Laaksonen et al., 2003; Kupelian et al., 
2010). Conversely, several studies have resulted with weak to non-existent associations 
between the two, leaving us yet in the dark (Maggio et al., 2006; Haring et al., 2012; 
Nakhai-Pour et al., 2007). 
Associations of Endogenous Testosterone Levels with Cardiovascular Disease and 
Mortality 
Incidence and Severity of Coronary Artery Disease 
Initial consensus of studies on the association of coronary artery disease (CAD) 
incidence with endogenous testosterone levels indicated that there was no significant 
relation (Cauley et al., 1987; Kabakci et al., 1999; Barrett-Connor et al., 1988; Arnlöv et 
al., 2006). The results have since changed as evidence increasingly has pointed to a 
negative association, with low testosterone levels indicative of an increasing CAD 
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incidence (Zhao & Li, 1998; English et al., 2000a; Dobrzycki et al., 2003; Akishita et al., 
2010; Rosano et al., 2007; Hu et al., 2011). These studies are shown in Table 1, as 
presented by Oskui et al. (2013). On a related note, several studies indicate that a more 
severe testosterone deficiency is linked to a more severe presentation of CAD (Dobrzycki 
et al., 2003; Rosano et al., 2007; Li et al., 2012; Philips et al., 1994).  
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Table 2: Association between Levels of Endogenous Testosterone and CAD 
Incidence. Table contrasts the studies that have found a significant association between 
testosterone levels and CAD incidence with studies that have not. It is important to note 
that English et al. and Rosano et al. were the only studies to use bioavailable testosterone 
(BT) for their assessment, both concluding with a significant association. BT may be a 
significant marker due to its active role as testosterone, as opposed to total testosterone 
(TT), which includes the non-active protein-bound portion. Next to each author’s name is 
the number of participants in the study, indicated by “n=#”. Abbreviations and 
clarification of terms are found below the table. Table taken from Oskui et al. (2013). 
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Cardiovascular Disease and All-Cause Mortality 
The research currently available regarding the association between mortality due 
to cardiovascular disease and endogenous TT levels is inconsistent. Haring et al. (2010), 
Khaw et al. (2007), and Smith et al. (2005) each found that lower levels of total 
testosterone significantly increased cardiovascular disease (CVD) mortality. On the other 
hand, Menke et al. (2010), Araujo et al. (2007), Vikan et al. (2009a), and Barrett-Connor 
et al. (1988) did not find such significant relation. Araujo et al. (2011) conducted a meta-
analysis including the aforementioned studies, collectively resulting in a 25% increased 
risk in CVD mortality with a drop in 2.18 standard deviations of endogenous TT levels. 
Although these results are shifted towards a negative association, they are not significant 
(RR=1.25; 95% CI, 0.97 to 1.60; P=0.06). Plus, the individual studies of the meta-
analysis had many differences amongst them (Araujo et al., 2011). The association 
between endogenous bioavailable testosterone (BT) levels and CVD mortality may be 
more telling, since BT solely consists of active levels of testosterone that may cause of 
any observed effects. The only three studies that observed this relation consistently 
showed significant increase in CVD mortality with lower bioavailable testosterone levels 
(Menke et al., 2010; Laughlin et al., 2008; Malkin et al., 2010). Araujo et al.’s (2011) 
meta-analysis also looked at the association of all-cause mortality and endogenous TT 
levels in 11 studies.  The result was a significant 35% increase in all-cause mortality risk 
associated with a decrease of 2.18 standard deviations of endogenous TT level (Haring et 
al., 2010; Khaw et al., 2007; Smith et al., 2005; Araujo et al., 2007; Menke et al., 2010; 
Vikan et al., 2009a; Tivesten et al., 2009; Szulc et al., 2009; Shores et al., 2006; Lehtonen 
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et al., 2008; Laughlin et al., 2008). However, similar caution should be taken with these 
results since the previously mentioned potentially confounding differences between 
studies also applied to this meta-analysis (Araujo et al, 2011). 
QTc Interval Length and Ventricular Arrhythmia 
 Prolonged instances of heart rate corrected QT (QTc) interval, or the time it takes 
for the ventricle to repolarize at a corresponding heart rate, are tied to increased risk of 
ventricular arrhythmia (Haverkamp et al., 2001). Evidence of the association between 
QTc interval and testosterone levels favors an inverse relationship (Pecori Giraldi et al., 
2010; Pecori Giraldi et al., 2011a; Pecori Giraldi et al., 2011b). Pecori Giraldi et al. 
(2010, 2011a, 2011b) showed in three different studies that three different populations of 
men with low testosterone levels, specifically hypogonadal, obese hypogonadal, and men 
with Cushing’s disease (a disease believed to lead to decreased testosterone levels), had a 
prolonged QTc interval. Van Noord et al. (2010) concluded with the same result, but had 
to combine the datasets of two separate, large studies with for a total of 1873 men to 
attain statistical significance (Van Noord et al., 2010).  
Intima-media thickness and Atherosclerosis 	  	   An increased intima-media thickness (IMT) of the carotid artery has been shown 
to increase risk of cardiovascular disease events such as myocardial infarction, stroke, 
and generalized atherosclerosis (Bots et al., 1996; Bots et al., 1997; O’Leary et al., 1999). 
The association between endogenous testosterone levels and carotid IMT is consistent in 
the evidence, namely an increased IMT with low testosterone levels, as displayed below 
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in Table 2 (Van den Beld et al., 2003; Fukui et al., 2003; De Pergola et al., 2003; 
Svartberg et al., 2006; Fu et al., 2008; Vikan et al., 2009b; Muller et al., 2004).  
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Congestive Heart Failure 
 Jankowska et al. (2006) have shown that congestive heart failure (CHF) patients 
have low levels of both TT and estimated FT that decrease in tandem with increasing 
CHF severity. They also were able to demonstrate that having decreased levels of 
multiple sex hormones, including both TT and estimated FT levels, led to increased CHF 
mortality in men. Interestingly, the results had no correlation to the left ventricular 
ejection fraction (LVEF), indicating that testosterone’s effects may not be directly acting 
on the heart (Jankowska et al., 2006). The results published by Wehr et al. (2011) further 
supports this finding as men with FT levels in the lowest quartile had a significantly 
increased risk of CHF mortality compared to the FT levels in the highest quartile (Wehr 
et al., 2011).  
An inability to exercise is considered one of the foremost symptoms of CHF, the 
limited blood flow from inadequate cardiac output impairing skeletal muscle function 
(Piña et al., 2003). Another way Jankowska et al. (2009) investigated the relationship 
between testosterone levels and CHF was through exercise capacity of the patients, using 
peak oxygen consumption (peak VO2) as one of several objective indices of exercise 
ability. Suitably, the only variable in the study that predicted worsening of exercise 
capacity as measured by peak VO2 was the testosterone levels. The correlation was 
positive, so only lower TT and FT levels significantly predicted decreasing capacity for 
exercise in a patient with CHF. According to these results, this correlation was 
presumably, and surprisingly, independent of CHF severity (Jankowska et al., 2009). 
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Associations of Testosterone Replacement Therapy with Cardiovascular Disease and 
Cardiovascular Risk Factors 
Angina Treatment 
 One of the earliest uses of testosterone replacement therapy (TRT) was for the 
treatment of angina pectoris. Both Lesser et al. (1946) and Levine & Likoff (1943) 
demonstrated testosterone’s beneficial effects through its administration to patients with 
angina. Recently, studies have shown that administering both chronic and acute 
testosterone therapy to men with coronary artery disease (CAD) improved exercise-
induced myocardial ischemia (English et al., 2000b; Rosano et al., 1999; Webb et al., 
1999a). Exercise-induced depression of the heart’s ST-segment in men with CAD has 
been shown to be a useful tool in monitoring the status of CAD (Deanfield et al., 1984). 
English et al. (2000b), Rosano et al. (1999), and Webb et al. (1999a) showed that TRT in 
men with CAD lengthened the time it took for ST-segment depression post-exercise, with 
greater improvements in men who had lower levels of testosterone. As a potential 
mechanism of how testosterone functions, Webb et al. (1999b) then demonstrated 
coronary vasodilation in response to testosterone infusion into the coronary arteries, a 
finding previously shown in the brachial artery of humans as well as in animal models 
(swine) (Ong et al., 2000; O’Connor, 2012).  
Congestive Heart Failure 
 Toma et al.’s (2012) meta-analysis has summarized the results of four studies that 
looked at the effects of TRT on exercise capacity in CHF patients. Consistent with the 
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studies of Jankowska et al. (2009), the meta-analysis concluded that four studies 
collectively showed that TRT significantly improved exercise capacity, independently of 
LVEF (Caminiti et al., 2009; Malkin et al., 2006; Pugh et al., 2004; Iellamo et al., 2010). 
Additionally, the study collected extra safety data revealing no significant differences in 
adverse cardiovascular events between the TRT and placebo groups.  
QTc Interval Length 
 Both Charbit et al. (2009) and Pecori Giraldi et al. (2010) have concluded with 
significant results of an inverse relationship between TRT and QTc interval length. Thus, 
testosterone substitution shortens the time it takes for the ventricle to repolarize as 
indicated by a shorter QTc interval length. Bai et al. (2005) provided evidence of 
testosterone’s potential mechanism of repolarizing the ventricle by demonstrating its 
action on membrane currents of the delayed rectifier potassium and L-Type calcium 
channels via nontranscriptional regulation. 
Cardiovascular Risk Factors 
 Evidence suggests that testosterone replacement therapy has a curative effect on 
the various aspects of glycemic control. Jones et al. (2011) and Kapoor et al. (2006) 
demonstrated that TRT significantly reduced homeostasis model assessment-estimated 
insulin resistance (HOMA-IR), one of the main causes of diabetes, allowing for better 
insulin sensitivity. Kapoor et al. (2006) also showed that as a result of the improved 
insulin sensitivity, hemoglobin A1c levels as well as fasting plasma glucose levels also 
significantly decreased via TRT in men with T2DM. With regards to obesity, 
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Kalinchenko et al. (2010) demonstrated that patient with metabolic syndrome who 
received TRT over a course of 30 weeks experienced significant decreases in BMI, waist 
circumference, weight, as well as insulin levels. Corona et al.’s (2011) meta-analysis 
contributed with evidence of TRT leading to an overall reduction of fat mass, fasting 
plasma glucose, and hemoglobin A1c. Effects of TRT on risk factors such as cholesterol 
levels and inflammatory markers have been less clear. Meta-analyses conducted by 
Haddad et al. (2007), Isidori et al. (2005), and Whitsel et al. (2001) all had varying results 
with regards to lipid levels. Haddad et al.’s meta-analysis (2007) found that TRT did not 
lead to significant changes in any of the lipid levels. On the other hand, Whitsel et al.’s 
meta-analysis (2001) concluded that intramuscular TRT resulted in small decreases in 
HDL cholesterol, LDL cholesterol and total cholesterol levels. Isidori et al.’s meta-
analysis (2005) was somewhere in the middle, with decreases in total cholesterol only in 
men that had low testosterone levels at baseline; decreases in HDL cholesterol only in 
men that had high testosterone levels at baseline; and no changes at all in LDL 
cholesterol. Similarly, available evidence of the effects of TRT on inflammatory markers 
is weak and inconsistent, as the data fluctuates between significant increases, significant 
decreases and non-significance for a range of markers (C-Reactive Protein (CRP), tumor 
necrosis factor-alpha (TNF-α), interleukin-6 (IL-6)) (Kalinchenko et al., 2010; Kapoor et 
al., 2007; Guler et al., 2006; Singh et al., 2002). 
Adverse Events 
 Since many studies have looked at the relationship between TRT and adverse 
events, this thesis will focus on the results of three major meta-analyses to summarize the 
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approach. Calof et al.’s (2005) meta-analysis included 19 studies with a total of 651 men 
receiving TRT and 433 placebo-controlled men. Results yielded that the TRT group had a 
significantly higher number of prostate events as well as a significant increase in 
hematocrit of >50% compared to the placebo group. However, no significant differences 
in cardiovascular related events were found between the groups (Calof et al., 2005). 
Haddad et al. (2007) reviewed 30 studies with a total of 1642 men, of which 834 were 
placebo-controlled and 808 were TRT-treated men. Haddad’s meta-analysis focused on 
the effects of TRT on blood pressure, lipid levels, and glycemic control, all of which they 
concluded were either small or negligible. Of the 30 studies, they employed six to assess 
the effects of TRT on adverse cardiovascular events, but were unable to find a significant 
association (Haddad et al., 2007). Fernandez-Balsells et al. (2010) performed the largest 
meta-analysis of the three, including 51 studies. Within these results, they found that TRT 
was significantly associated with increases in hemoglobin and hematocrit, similar to the 
results found by Calof et al. (2005). Nonetheless, the main finding was that 
cardiovascular events, all-cause mortality, and prostatic events were all non-significantly 
associated to TRT (Fernandez-Balsells et al., 2010). Studies of conflicting results 
reporting increased adverse events associated with TRT have been discussed at length in 
sections above (Basaria et al., 2010; Xu et al., 2013; Vigen et al., 2013; Finkle et al., 
2014).    
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DISCUSSION 	  
Analysis Of The Case Against Testosterone Replacement Therapy 
Though the TOM trial provides results indicating significant cardiovascular risk 
due to testosterone therapy, severe limitations crucially undermine the conclusion of 
these results (Basaria et al., 2010). The initial design of Basaria et al.’s TOM Trial was 
meant to measure the change in strength of participants taking TRT as compared to 
baseline. Since the study was in no way prepared to measure and systematically evaluate 
cardiovascular events, the resulting reported incidents were not collected in a 
scientifically verifiable and reproducible method. As such, events were self-reported by 
physicians post examination, or derived from medical records, each of which leave the 
results vulnerable to bias and discrimination. Without initially defining which symptoms 
constitute a cardiovascular event caused by testosterone therapy, mild symptoms with 
ambiguous origin, such as “peripheral edema”, “elevated blood pressure”, and “syncope”, 
were counted as purely cardiovascular events. Revisiting the baseline health of these 
men, whose age averaged at 74, reveals that of the TRT group, 85% were hypertensive, 
45% were obese, 53% had preexisting cardiovascular disease, 63% had hyperlipidemia, 
and 24% had diabetes mellitus. Considering their old age, limited mobility, and 
preexisting conditions, the inclusion criteria of this trial had already selected a population 
that was at a high risk for cardiovascular-related events. Even so, the sample size of 
participants was small, as was the consequent number of adverse events, diminishing the 
statistical power and significance of the study. A comparable study conducted by 
Srinivas-Shankar et al. (2010) concluded there was a lack of adverse events in the TRT 
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group compared to the placebo group. The authors went so far as to concede that the 
results might simply be coincidental due to the random variety and small number of the 
reported events. As the oldest of the four studies associating testosterone replacement 
therapy with increased cardiovascular risk, the TOM trial is in a position to set the stage 
for the argument against testosterone therapy and to provide a valid foundation for 
subsequent studies. The conclusion of this study does neither of the above (Basaria et al., 
2010). 
 Xu et al.’s (2013) study is the only meta-analysis concluding that TRT 
significantly increases risk of cardiovascular disease. Of other meta-analyses that have 
also looked at the effects of TRT, Whitsel et al.’s (2001) meta-analysis of TRT effects on 
lipid levels was unable to conclude its relation to cardiovascular (CV) risk. Toma et al.’s 
(2012) meta-analysis of TRT effects on exercise capacity of men with chronic heart 
failure concluded with no associated significant cardiovascular adverse events. Isidori et 
al.’s (2005) meta-analysis reviewed the generalized effects of testosterone therapy and 
while it did not specifically consider cardiovascular risk, it suggested that the fat-
reducing effects of testosterone could have a positive effect on CV risk. The Fernandez-
Balsells et al. (2010) study, one of three large meta-analyses that directly assessed TT’s 
risk of adverse events, concluded that there was no significant effect on cardiovascular 
outcome. Both Haddad et al. (2007) and Calof et al. (2005) were also unable to conclude 
any significant adverse cardiovascular effects of testosterone replacement therapy.   
 That the results of Xu et al. do not fit with previous results is largely attributable 
to the inclusion of two questionable trials, which inappropriately contributed to a 
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significant proportion of its primary endpoints. A closer look at the trials reveals that the 
two studies with the greatest contribution of adverse TRT related events were Basaria et 
al.’s TOM Trial and the Compenhagen Study Group (Basaria et al., 2010; Copenhagen 
Study Group, 1986). We already established the TOM trial as an unreliable foundation of 
evidence build upon. Likewise, the Copenhagen Study (1986) administered an oral 
testosterone preparation to men with liver cirrhosis to observe its effects on liver 
function, thus providing the second largest number of adverse testosterone events (16) to 
the meta-analysis. The oral testosterone was administered at a rate of 200mg/8 hours, 
resulting in 600mg/day, leading to testosterone levels of over 4000 ng/dl in about 25% of 
the men (Copenhagen Study, 1986). According to the Androgen Study Group’s letter to 
the FDA, oral testosterone has a history of association with hepatotoxicity upon first pass, 
an effect that was likely emphasized when administered at supraphysiologic levels to men 
with liver disease (Androgen Study Group, 2014a). Due to the introduction of a harmful 
confounding factor that undoubtedly influenced mortality, the Copenhagen study is 
justifiably unsuitable for the analysis. Excluding the events of the Copenhagen Study and 
the TOM trial, the Androgen Study Group correctly points out that the risk of the 
testosterone group decreases to 4.88% (78 events/1599 men), which is lower than the 
5.1% of the placebo group (60 events/1174 men) (Androgen Study Group, 2014a). 
A study is understandably limited by what it defines as its endpoints. Xu et al. 
(2013) narrowed down the meta-analysis to 27 trials by including only studies that 
reported cardiovascular events. Studies that either did not have or did not report any CV 
events or had an insignificant number of events were deemed unworthy of inclusion by 
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the authors. As a result, the absolute proportion of events and the relative rate of events 
between the placebo and testosterone therapy groups may be skewed. The authors may 
have found what they were looking for, but it was at the expense of accurately 
representing the pool of available evidence. Hence, with all these issues, Xu et al. (2013) 
make it difficult for the argument against testosterone replacement therapy to gain 
legitimate traction. 
 Within a year since publishing, Vigen et al. (2013) have submitted two official 
corrections to their original script, attracting a potent backlash from the medical 
community. Additionally, they are under pressure from the Androgen Study Group 
(ASG), who requested withdrawal of their article through a letter to JAMA (ASG, 2014b; 
Vigen, 2014a; Vigen, 2014b). The ASG has compiled an extensive list of 29 medical 
societies and over 150 medical experts from around the world citing the study as fatally 
flawed and a source of misinformation (ASG, 2014c). On first look, perhaps the largest 
fault was the study’s rigorous weighting system, whose unprecedented impact completely 
reversed the outcome of the raw data (Vigen et al., 2013; ASG, 2014b). Without 
application of the weighting system, the initial percentages of events were only 10.1% 
(123 events/1223 men) in the TRT group compared to 21.2% in the placebo group (1587 
events/1587 men). Only after applying the weighting system did TRT seem to result in 
increased cardiovascular risk (Vigen et al., 2013; ASG, 2014b).  
The study also has a host of troubling issues in its methods and results. The 
average testosterone level rose from 175.5 ng/dL to 332.2 ng/dL at the first post-
treatment testosterone measurement, testosterone levels that are still low (Vigen et al., 
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2013; Endocrine Society Guidelines, 2010). The Endocrine Society Clinical Guidelines 
recommend being in the mid-normal range, meaning these men were potentially 
undertreated (Endocrine Society Guidelines, 2010). A lack of data is no justification for 
assumption, yet these men were assumed to be compliant once prescribed even though 
there was no data to confirm it (Vigen et al, 2013). A closer look at the forms of 
testosterone administered revealed that 63.3% received a 2.5mg/24 hour testosterone 
patch, a low dosage by conventional patch standards (5-7mg/24 hours) and inconsiderate 
of the high dropout rate caused by irritation from the patches (Srinivas-Shankar & Wu, 
2006; Vigen et al., 2013). Since only 17.6% of the men refilled once, this does not stand 
as evidence for a long-term treatment of testosterone. In addition, the study design did not 
initially separate the two groups based on controlled variables. Data collection started 
with coronary angiography initiation, initially placing all participants in the no 
testosterone therapy group. Participants were switched over to the TRT group only once 
they started receiving testosterone replacement therapy for reasons that were not 
documented. In this way, a potentially confounding imbalance is created in the study 
data, as everyone contributes to non-testosterone therapy data, but not everyone 
contributed to the testosterone therapy data (Vigen et al., 2013).  
Nonetheless, these flaws are belittled when questioning the very credibility of the 
study. Vigen et al.’s (2013) two corrections stemmed from incorrect language use and 
presentation of data (Vigen 2014a; Vigen 2014b). The first amendment required changing 
a statement of how the main results were presented in the abstract (Vigen, 2014a). The 
“absolute rate of events” was altered to the “Kaplan-Meier estimated cumulative 
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percentages” of events, a crucial modification considering the heavy reliance of statistics 
in the study and essentially changing how one were to interpret the results (Vigen, 2014a; 
Androgen Study Group, 2014a). The second correction specifically regarded a mistake in 
the presentation of how many people were excluded from the study (Vigen, 2014b; 
Androgen Study Group, 2014a). Numbers were drastically readjusted, from excluding 
1132 men who “had testosterone therapy prescribed after MI or stroke” to excluding 128 
men instead; from excluding 397 men with missing coronary anatomy data to 1301 
instead; and excluding an additional 100 women who were previously excluded without 
mention (Vigen, 2014b; ASG, 2014a). As stated in a letter written by the Androgen Study 
Group (2014b) to the JAMA editors, the above changes constitute an 89% error rate, a 
44% error rate, and failure to mention the presence of women in an all-male study, 
respectively. The changes may also stand as evidence of “misconduct or honest error”, 
both of which qualify the study for retraction according to guidelines of the Committee 
On Publication Ethics (COPE) (ASG, 2014a). As such, Vigen et al.’s study (2013) and 
any of its conclusions are effectively invalidated as argument against TRT.  
 The final study claiming increased cardiovascular risk due to TRT, conducted by 
Finkle et al. (2014), has its own issues with study design and is limited by its use of an 
insurance database. By assigning the pre prescription period as the 12 months prior to 
being prescribed TT, Finkle et al. neglected the possibility that the uncontrolled physician 
care and treatment of each patient during this period could have influenced the results of 
the post prescription period that follows. Much can change for the patients within twelve 
uncontrolled months, including their risk of cardiovascular disease or their need for a 
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TRT prescription. Furthermore, the study design is flawed in itself by comparing two 
uncontrolled periods, namely this pre prescription period with a post prescription period 
that reflects the direct effects of treatment. Comparing these two periods is like 
comparing two completely different factors and simply will not show accurate 
information without adequate control (Finkle et al., 2014). 
 Unsurprisingly, the faultiness of the methodology carries on to the rest of the 
study. Without a true control group that does not receiving TRT, the post prescription 
results have nothing to compare against to indicate whether was a significant 
improvement. Finkle et al. (2014) chose to use PDE5I as a comparison group, but the 
comparison is invalid and cannot be relied for realistic appraisal, as the medications, 
indications, and patient populations of the two drug groups were all completely different 
from each other (Healthwise Staff, 2012). Moreover, the primary endpoint, non-fatal MI, 
was acquired from a database that did not have additional information to validate its 
accuracy, such as the actual test results or other evidence for diagnosis. In such a case, 
the accuracy of the data could be adjusted with an algorithm (Petersen et al., 1999), but 
since this was not done, the data is likely inaccurate to a certain degree (ASG, 2014a). 
The pre prescription and post prescription MI risk rates, 3.48 per 1000 person-years and 
4.75 per 1000 person years, respectively, were comparatively lower than the predicted 
values of the NIH heart attack risk calculator (13 per 1000 person-years) when estimating 
parameters for an otherwise healthy man (average age of 54 same as patient population; 
total cholesterol 230mg/dL; HDL 40mg/dL; non smoker; Systolic Blood Pressure at 
140mm/Hg; on medication for hypertension) (NIH, 2013; ASG, 2014a). This adds 
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additional doubt to the reliability of the numbers. Ultimately, with a weak foundation set 
by the previous studies, Finkle et al.’s (2014) study is too flawed with unreliable methods 
and assumptions to hold any justifiable weight as evidence against testosterone 
replacement therapy. 
Summary Of Evidence Concerning Endogenous Testosterone Levels, 
Testosterone Replacement Therapy and Cardiovascular Health 
 For organizational purposes, the following subsections include summaries of the 
results of both endogenous testosterone levels and testosterone replacement therapy in 
relation to cardiovascular health and risk factors. This is in slight variation to how they 
were presented above in the “Published Studies” section. 
Type 2 Diabetes Mellitus 
 Evidence has consistently shown that diabetic men have lower endogenous total 
testosterone, free testosterone, and SHBG levels than non-diabetic men (Shahwan et al., 
1978; Andò et al., 1984; Barrett-Connor et al., 1990; Ding et al., 2006; Corona et al., 
2011). Risk of developing T2DM has also been shown to increase with decreasing levels 
of TT, FT, and SHBG (Colangelo et al., 2009; Laaksonen et al., 2004; Vikan et al., 2010; 
Keating et al., 2010). Finally, testosterone replacement therapy has proven beneficial in 
improving the glycemic control of diabetic patients through reductions in insulin 
resistance, plasma fasting glucose, insulin, and hemoglobin A1c (Jones et al., 2011; 
Kapoor et al., 2006; Kalinchenko et al., 2010).  
 Though our knowledge of the interaction between testosterone and type-2 
diabetes mellitus is based on reliable evidence, details of the relationship are still poorly 
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understood. One mechanism of testosterone action may be through its effects on visceral 
adipose tissue, which is known to interact with insulin resistance (Kapoor et al., 2005). 
Androgens have been shown to enhance lipolysis, decreased fat mass, and prevent 
differentiation of adipocytes, which lessens their accumulation of lipids (Gupta et al., 
2008; Corona et al., 2011; Kalinchenko et al., 2010). Part of the interaction may also be 
due to a lack of insulin. Type-2 diabetic men have been shown to have an increased 
incidence of hypogonadotropic hypogonadism, possibly because insulin deficiency 
prevents adequate activation of the hypothalamus to release gonadotropin-releasing 
hormone (Dhindsa et al., 2004). These results indicate a potential two-way relationship 
between testosterone and diabetes, which may only be fully determined through more 
trials. 
Obesity 
 Low endogenous levels of total testosterone have been reliably associated with 
higher BMI (MacDonald et al., 2009; Mulligan et al., 2006; Ohlsson et al., 2011). In turn, 
testosterone replacement therapy has resulted in significant decreases in fat mass and 
BMI (Kalinchenko et al., 2010; Corona et al., 2011). As is the case with type-2 diabetes, 
though the precise mechanism of interaction between testosterone and obesity is not 
understood, there are certain ideas of how it may be functioning. Testosterone may be 
acting through its previously mentioned lypolytic effects on fat. Conversely, the visceral 
obesity may be disturbing the release of testosterone through its action on the 
hypothalamic-pituitary-testicular axis (Wu et al., 2008). Interestingly, an increase in 
aromatase due to extra adipose tissue could be inducing hypogonadism through excessive 
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conversion of testosterone to estrogen (Nimrod & Ryan, 1975; Cohen, 2001). More 
research must be done to clarify the matter. 
Dyslipidemia 
The cross-sectional data reporting associations between cholesterol levels and 
endogenous testosterone levels is conflicting, based on inadequate sample sizes, and 
requires further research for clarification (Haffner et al., 1993; Van Pottelbergh et al., 
2003; Wranicz et al., 2005; Agledahl et al., 2008; Vaidya et al., 2008). To date, the 
relation between endogenous testosterone levels and dyslipidemia has not been explored 
in a large prospective study (Oskui et al., 2013). Data concerning the effects of 
testosterone replacement therapy on lipid levels is also conflicting (Haddad et al., 2007; 
Isidori et al., 2005; Whitsel et al., 2001). The lack of consistent information may be due 
to the wide variability of lipid levels in the population as well as our limited 
understanding of them.  Further research is needed to gain a perspective. 
Inflammatory Markers 
 Out of the many inflammatory markers, most studies have looked at the 
association of high-sensitivity C-reactive protein (hsCRP) with endogenous testosterone 
levels. The results have been contradictory. Testosterone has been negatively correlated 
to hsCRP (Bhatia et al., 2006; Zhang et al., 2013; Kapoor et al., 2007; Laaksonen et al., 
2003; Kupelian et al., 2010). Testosterone has also shown no association with hsCRP 
(Maggio et al., 2006; Haring et al., 2012; Nakhai-Pour et al., 2007). The research on TRT 
and inflammatory markers is similarly conflicting (Kalinchenko et al., 2010; Kapoor et 
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al., 2007; Guler et al., 2006; Singh et al., 2002). Inflammatory markers are difficult to 
study due to their transient nature and our lack of knowledge on the topic. More research 
must be done. 
Coronary Artery Disease 
 Although early studies were not significant (Cauley et al., 1987; Kabakci et al., 
1999; Barrett-Connor et al., 1988; Arnlöv et al., 2006), results have more recently 
demonstrated that low testosterone levels correlated to an increased CAD incidence 
(Zhao & Li, 1998; English et al., 2000a; Dobrzycki et al., 2003; Akishita et al., 2010; 
Rosano et al., 2007; Hu et al., 2011). A couple of reasons may account for this swing in 
results. According to Table 1, none of the articles that failed to show an association 
included bioavailable testosterone (BT) in their analysis. Though not proven, BT may be 
a better indicator of testosterone activity than free testosterone (FT), thus explaining the 
change in results. In addition, only one of the “non-associative” articles used the better 
means of measuring CAD in the patients with cardiac catheterization, but it still lacked 
BT measurements (Kabakci et al., 1999). Increasing CAD severity has been linked to 
lower endogenous testosterone levels (Dobrzycki et al., 2003; Rosano et al., 2007; Li et 
al., 2012; Philips et al., 1994). An overview of all the above studies, including those in 
Table 1, reveals their relatively small sample sizes. Due to a lack of power, the results 
should be interpreted with restraint. Also, the relation of causality between testosterone 
levels and CAD remains to be determined. Larger additional prospective trials are needed 
to strengthen our understanding of this association.  
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 Testosterone replacement therapy has been shown to lengthen the time till 
exercise-induced ST-segment depression, improvement of a parameter measuring CAD 
(English et al., 2000b; Rosano et al., 1999; Webb et al., 1999a). The potential mechanism 
of testosterone function is presumed to be vasodilation, though it is not yet clear how it 
acts on the vessels (Webb et al., 1999b; Ong et al., 2000; O’Connor, 2012). More 
research is necessary. 
Congestive Heart Failure 
 Only a few studies have shown that lower levels of testosterone correlate with 
increasing CHF severity and mortality (Jankowska et al., 2006; Wehr et al., 2011). 
Jankowska et al. (2009) has also confirmed that lower testosterone levels predicted lesser 
exercise capacity, independent of CHF severity. Testosterone replacement therapy also 
showed significant improvement in exercise capacity independently of LVEF (Caminiti 
et al., 2009; Malkin et al., 2006; Pugh et al., 2004; Iellamo et al., 2010). Since effects of 
TRT have been independent of LVEF in all the current evidence on the topic, Oskui et al. 
(2013) postulate that testosterone may be improving exercise capacity by increasing 
peripheral Type I fibers of the skeletal muscles, as opposed to directly acting on the Type 
II muscle fibers of the heart. Regardless, more studies with ample sample size should be 
conducted to solidify the initial findings of Jankowska et al. (2009) and to better 
understand this mechanism.  
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Cardiovascular Disease and All Cause Mortality 
 The association between endogenous testosterone levels and cardiovascular 
mortality is inconsistent (Haring et al., 2010; Khaw et al., 2007; Smith et al., 2005; 
Menke et al., 2010; Araujo et al., 2007; Vikan et al., 2009a; Barrett-Connor et al., 1988). 
A meta-analysis regarding the association shows a non-significant negative trend (Araujo 
et al., 2011). Interestingly, Araujo et al.’s (2011) meta-analysis relating all cause 
mortality with endogenous testosterone levels shows a significant negative association 
(Haring et al., 2010; Khaw et al., 2007; Smith et al., 2005; Araujo et al., 2007; Menke et 
al., 2010; Vikan et al., 2009a; Tivesten et al., 2009; Szulc et al., 2009; Shores et al., 2006; 
Lehtonen et al., 2008; Laughlin et al., 2008). Both meta-analyses suffer from substantial 
differences between the studies, such as significant variety in age, baseline TT levels, 
follow-up period length, and daily time of blood sampling (Araujo et al., 2011). Also, the 
sample sizes of the studies are small. The mechanism of testosterone’s action in relation 
to mortality is still unknown. All of these are reason for further study. 
Atherosclerosis (Intima-Media Thickness)  
 Low endogenous testosterone levels are consistently associated with an increased 
IMT (Van den Beld et al., 2003; Fukui et al., 2003; De Pergola et al., 2003; Svartberg et 
al., 2006; Fu et al., 2008; Vikan et al., 2009b; Muller et al., 2004). However, according to 
Table 2, the sample sizes are small and the studies vary in certain variables observed. 
Follow-up prospective studies with larger sample sizes should be done to verify these 
results and attempt to understand the mechanism of testosterone’s action. 
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QTc Interval 
 Evidence shows that men with low levels of testosterone have lengthened QTc 
intervals, indicating increased risk of ventricular arrhythmia (Pecori Giraldi et al., 2010; 
Pecori Giraldi et al., 2011a; Pecori Giraldi et al., 2011b; Van Noord et al., 2010). TRT 
has demonstrated a shortening of the QTc interval (Charbit et al., 2009; Pecori Giraldi et 
al., 2010). A potential mechanism for testosterone is by modifying the membrane 
currents of ion channels through non-transcriptional regulation (Bai et al., 2005). These 
studies need to be confirmed by larger trials with more participants for validation and 
clinical relevance.  
Adverse events 
 Three large meta-analyses with a total of a 100 studies were unable to find 
significant association of TRT with adverse cardiovascular or prostatic events (Calof et 
al., 2005; Haddad et al., 2007; Fernandez-Balsells et al., 2010). TRT was significantly 
associated with increases in hemoglobin and hematocrit (Calof et al., 2005; Fernandez-
Balsells et al., 2010). Regardless, the only way to adequately assess the safety of TRT is 
through a large randomized placebo-controlled prospective trial.  
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CONCLUSIONS 	  
As a disease, late-onset hypogonadism exists by virtue of threading a thinly 
balanced line between reality and construct, bearing a definition fundamentally based on 
measurements of the subjective and the unknown. Its defining symptoms overlap with old 
age and are inevitably subject to the whims of the patients they afflict, while testosterone 
thresholds have yet to be reliably standardized, and thus may still fluctuate measurement-
to-measurement, day-to-day, person-to-person, guideline-to-guideline. Testosterone 
replacement therapy is in a precarious position as a drug for LOH. Pharmaceutically, 
sales and prescriptions have only risen in recent years with the aid of marketing and 
lenient guidelines. On the other hand, conclusive scientific evidence in the form of a 
randomized controlled trial is still lacking, and the question still remains whether its 
benefits outweigh the risks. Recent evidence of TRT increasing cardiovascular risk has 
threatened the drug’s image and shaken the public’s confidence.  
 Over the course of 10 years, from 2001 to 2011, androgen prescribing in men over 
40 years old in the United States has tripled (Baillargeon et al., 2013). Globally, total 
testosterone prescriptions have risen 12-fold over 11 years (2000-2011), transforming 
from a $150 million dollar market to a $1.8 billion dollar market, and predicted to reach 
$5 billion by 2018 (Handelsman, 2013; Global Industry Analysts, 2013). Off-label 
testosterone prescriptions have increased in 37 out of 41 countries without the addition of 
any new indications. Of these 41 countries, Canada and the United States had the steepest 
increases in prescriptions (Handelsman, 2013). One part of the reason could be the 
guidelines themselves, published midway through this period, defining late-onset 
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hypogonadism and recommending off-label testosterone replacement therapy prescription 
if diagnosed (Endocrine Society Clinical Guidelines, 2010; Wang et al., 2009; 
Handelsman, 2013). Another reason could be the major “Low T” disease awareness 
campaign, part of an upswing in direct-to-consumer advertising within North America 
(Braun, 2013; Schwartz & Woloshin, 2013). This campaign was funded by 
pharmaceutical companies making TRT and directed at physicians and consumers to 
influence how they think about late-onset hypogonadism, or “Low T” (Braun, 2013; 
Schwartz & Woloshin, 2013). Either way, the rising concern is that the safety of these 
increasing testosterone sales to treat LOH has not been confirmed by a large, randomized, 
placebo-controlled trial.  
 Without an authoritative study to bless the safe use of testosterone replacement 
therapy for LOH, the recent studies by Vigen et al. (2013) and Finkle et al. (2014) 
basically attempted to fill this role and possibly curb the giant market of TRT. 
Unfortunately, these studies (including Basaria et al. (2010) and Xu et al. (2013)) were 
flawed in design and conduct, resulting in more misinformation and damage to public 
knowledge, a backfiring of sorts. With the results of these studies publicized, any attempt 
to caution the public on the safety of TRT for LOH use was erroneously out of 
proportion. Even so, this situation is currently being dealt with through an FDA 
investigation on the risk of stroke, heart attack and death with FDA-approved 
testosterone products (FDA, 2014a). And yet, the question still remains whether there’s 
any cardiovascular risk to using testosterone replacement therapy for LOH. Generally 
speaking, the current evidence leans heavily towards cardiovascular safety, and even 
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cardiovascular improvements with testosterone replacement. According to the evidence, 
low testosterone levels were actually most associated with increased cardiovascular risk 
and mortality. With that said, many of the studies were conducted with small sample 
sizes, may have been lacking adequate power, and were purely epidemiological. The 
FDA has also recently added a black-box warning to another risk of testosterone 
products, specifically their potential to cause venous blood clots not related to 
erythrocytosis (FDA, 2014b). Although a large, randomized, multi-location, placebo-
controlled trial is currently being conducted (the T Trial), the current evidence of TRT 
effects on cardiovascular risk must be reviewed with caution (Synder, 2014). As with any 
medical decision, one must weigh the benefits against the risks. The best choice is catered 
to the individual, made by listening to the severity of one’s symptoms, evaluating their 
effects on one’s quality of life, and by discussing an appropriate approach in cooperation 
with a physician.  
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